Allspring Global Investments Holdings LLC Lowers Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Allspring Global Investments Holdings LLC cut its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 14.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 181,122 shares of the company’s stock after selling 29,409 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.47% of Tarsus Pharmaceuticals worth $10,029,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of TARS. China Universal Asset Management Co. Ltd. boosted its position in Tarsus Pharmaceuticals by 10.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,106 shares of the company’s stock valued at $449,000 after acquiring an additional 789 shares in the last quarter. R Squared Ltd purchased a new position in shares of Tarsus Pharmaceuticals in the 4th quarter valued at approximately $53,000. Franklin Resources Inc. lifted its stake in shares of Tarsus Pharmaceuticals by 9.3% in the 3rd quarter. Franklin Resources Inc. now owns 12,164 shares of the company’s stock valued at $444,000 after purchasing an additional 1,033 shares during the period. SG Americas Securities LLC boosted its position in shares of Tarsus Pharmaceuticals by 87.5% during the third quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock valued at $238,000 after purchasing an additional 3,379 shares in the last quarter. Finally, FMR LLC grew its stake in Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after purchasing an additional 3,537 shares during the period. 90.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TARS has been the topic of a number of recent analyst reports. The Goldman Sachs Group raised their price target on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. Guggenheim reiterated a “buy” rating on shares of Tarsus Pharmaceuticals in a research report on Monday, February 10th. Oppenheimer raised their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. Finally, Barclays upped their target price on shares of Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research report on Monday, January 27th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Tarsus Pharmaceuticals has a consensus rating of “Buy” and an average price target of $56.00.

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock opened at $50.85 on Wednesday. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The firm has a market capitalization of $1.94 billion, a PE ratio of -13.35 and a beta of 1.01. The firm has a 50-day moving average price of $52.06 and a 200-day moving average price of $42.19. Tarsus Pharmaceuticals, Inc. has a 12-month low of $20.08 and a 12-month high of $57.28.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.